$1.38
2.13% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US65343E1082
Symbol
NXTC
Sector
Industry

NextCure, Inc. Stock price

$1.38
-0.20 12.66% 1M
-0.56 28.68% 6M
+0.24 21.05% YTD
+0.07 5.34% 1Y
-5.57 80.14% 3Y
-31.37 95.79% 5Y
-13.62 90.80% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.03 2.13%
ISIN
US65343E1082
Symbol
NXTC
Sector
Industry

Key metrics

Market capitalization $39.45m
Enterprise Value $-40.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.88
P/B ratio (TTM) P/B ratio 0.46
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-63.66m
Free Cash Flow (TTM) Free Cash Flow $-46.46m
Cash position $86.44m
EPS (TTM) EPS $-2.20
P/E forward negative
Short interest 0.30%
Show more

Is NextCure, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

NextCure, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a NextCure, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a NextCure, Inc. forecast:

Buy
100%

Financial data from NextCure, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 3.41 3.41
26% 26%
-
-3.41 -3.41
26% 26%
-
- Selling and Administrative Expenses 10 10
19% 19%
-
- Research and Development Expense 47 47
9% 9%
-
-60 -60
12% 12%
-
- Depreciation and Amortization 3.41 3.41
26% 26%
-
EBIT (Operating Income) EBIT -64 -64
13% 13%
-
Net Profit -61 -61
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about NextCure, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NextCure, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab was ...
Neutral
GlobeNewsWire
3 months ago
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.
Neutral
GlobeNewsWire
4 months ago
BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will b...
More NextCure, Inc. News

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Head office United States
CEO Michael Richman
Employees 82
Founded 2015
Website www.nextcure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today